Anacor Pharmaceuticals

Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

Type
Public
HQ
Palo Alto, US
Founded
2002
Employees
110 (est)
Anacor Pharmaceuticals was founded in 2002 and is headquartered in Palo Alto, US

Anacor Pharmaceuticals Locations

Palo Alto, US

Anacor Pharmaceuticals Metrics

Anacor Pharmaceuticals Financials

Anacor Pharmaceuticals's revenue is $82.4 M in FY, 2015 which is 298.12% increase from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Revenue

$17.2 M$20.7 M$82.4 M

Cost of goods sold

$797 K$4.02 M

Gross profit

$19.9 M$78.3 M

Operating income

$92.5 M$-90.8 M$-56.4 M

Operating expense total

$-75.3 M$111 M$139 M

Interest expense

$2.01 M$1.4 M$2.91 M$4.15 M$4.71 M$5.54 M

Income tax expense

$1.71 M$-10.3 M

Net Income

$84.8 M$-87.1 M$-61.2 M

Operating cash flow

$104 M$-98.8 M$37.7 M

    Anacor Pharmaceuticals News

    Anacor Pharmaceuticals Company Life

    You may also be interested in